













Neonatal diabetes — same disease, same gene, 
different outcomes
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Neonatal diabetes mellitus (NDM) is a rare disease 
[1–4], occurring in approximately 1 in 100,000–200,000 
live births [1]. The condition may be transient or per-
manent [1–5] and is most often caused by monogenic 
defects [2–4].
KCNJ11 gene mutations represent the most common 
cause of permanent NDM (PNDM) [2, 5] but are only 
rarely implicated in transient NDM (TNDM) [2]; the 
underlying mechanism differentiating these pheno-
types is still unclear [1].
While its use is still considered off-label in the paedi-
atric population [1, 4, 5], sulfonylureas have become the 
mainstay of treatment for patients with KCNJ11-related 
NDM [1–5].
We herein present two case reports of patients 
with overlapping early presenting conditions, which, 
although they carried the same mutated gene, had 
acutely different outcomes.
Patient no. 1, a three-month-old female infant, with no 
relevant priors, was evaluated in a neighbouring hospi-
tal for respiratory distress and irritability in the previous 
24 hours. She was hypotensive and dyspnoeic, and 
blood tests reflected dehydration and showed severe 
hyperglycaemia and elevated ketone bodies, for which 
diabetic ketoacidosis (DKA) was suspected. Intravenous 
(IV) hydration and insulin perfusion were started, and 
she was transferred to our hospital’s Paediatric Inten-
sive Care Unit (PICU).
The patient’s condition improved progressively 
under IV insulin perfusion, acidosis resolved, and both 
glycaemia and ketonaemia normalised.
Blood testing revealed negative anti-insulin and 
anti-GAD antibodies, and an ultrasound confirmed 
a macroscopically normal pancreas. Due to the patient’s 
age and clinical presentation, a genetic study for pos-
sible causes of NDM was requested.
After five days in the PICU, the patient was switched 
to subcutaneous insulin therapy and was subsequently 
transferred to our paediatrics general ward. After 
adequate glycaemic control was attained under a bas-
al-bolus scheme, she was discharged (day 26).
After discharge, despite being under the same 
subcutaneous insulin scheme, blood glucose levels 
remained erratic (HbA1c 8.5–11.4%). At nine months, 
genetic study results revealing a KCNJ11 mutation 
— c.602G>A (p.Arg201His) were received, confirming 
the diagnosis of NDM. After approval from responsible 
entities, the switch to off-label therapy with gliben-
clamide was successfully performed in an inpatient 
setting.
Afterwards, during the six years of follow-up in 
our institution, the patient was managed successfully 
under exclusive sulfonylurea treatment (HbA1c 5.4–7%) 
— hypoglycaemic episodes were rare and no further 
insulin therapy was necessary.
Patient no. 2, a two-month-old male infant, with no 
relevant medical history, was assisted in another 
local hospital for refusal to feed, vomiting, and ap-
parent respiratory distress. On exam, the infant was 
ill-appearing, dyspnoeic, and had a prolonged capillary 
perfusion time. Initial blood testing showed metabolic 
acidosis with ketonaemia and blood glucose levels over 
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and the threshold for requesting genetic testing should 
be low [3–5] — genetic diagnosis may not only confirm 
suspicions, but also directly impact management strate-
gies, as with the use of sulfonylureas in patients with 
KCNJ11 mutations [1, 3–5].
As reflected by our report, despite being otherwise 
useful, the detection of a KCNJ11 mutation does not 
accurately predict the patient’s outcome because, al-
though mostly associated with PNDM, this mutation 
may also cause transient forms of the condition.
Infancy-onset diabetes should prompt early genetic 
testing for NDM [3–5]. Close monitoring of NDM 
patients who carry a KCNJ11 mutation is crucial, and 
the possibility of a transient form should always be 
considered.
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500 mg/dL. Intravenous hydration was initiated, and 
the patient was brought to our institution’s PICU.
On admission, after initial assessment and review 
of the previous blood test results, DKA was diagnosed 
and IV insulin perfusion was started.
Both anti-GAD and anti-insulin antibody screenings 
were negative, and ultrasound revealed an apparently 
normal pancreas. A genetic study for NDM-associated 
mutations was requested.
The patient progressively improved, initially under 
IV insulin infusion, and then from day 5 (when he was 
transferred to our General Paediatrics Ward) under 
continuous subcutaneous insulin infusion (CSII). He 
was discharged on day 13, after glycaemic stability was 
attained and the parents were familiar with the system.
After discharge, the patient remained euglycaemic 
under CSII but needed progressively lower insulin dos-
ages until, at five months of age, insulin therapy was 
suspended definitively.
At eight months of age genetic testing results were 
obtained, detecting a KCNJ11 mutation — c.149G>A 
(p.Arg50Gln).
He is currently three years old and remains nor-
moglycaemic.
Neonatal diabetes mellitus most often presents within 
the first six months of life, frequently as DKA [4, 5], as 
was the case with our two patients. Nonetheless, this 
condition should still be considered in patients up to 
12 months of age, and its course may be insidious or 
even subclinical at onset [4].
When evaluating infants with DKA or even ap-
parently persistent hyperglycaemia, a high level of 
suspicion toward NDM is of the upmost importance, 
